SCHEMBL3377083

SCHEMBL3377083

CS(=O)(=O)Nc1ccc(-c2ccc(F)c(Cl)c2)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.52
KIF11 P52732 2/20 0.51
FABP4 P15090 2/20 0.48
FABP5 Q01469 2/20 0.48
HPGD P15428 2/20 0.48
GAA P10253 1/20 0.48
MAPK1 P28482 1/20 0.48
DRD2 P14416 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
DRD3 P35462 1/20 0.47
HTR6 P50406 1/20 0.47
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
PKM P14618 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PTGS1 P23219 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3374747 0.91 KIF11 (0.51) PTGS2KIF11HPGDGAAMAPK1
SCHEMBL3378146 0.89 CYP17A1 (0.54) PTGS2KIF11FABP4FABP5HPGD
SCHEMBL3376954 0.89 KIF11 (0.48) PTGS2KIF11HPGDGAAMAPK1
SCHEMBL11233219 0.88 MEN1 (0.55) KIF11HPGDGAAMAPK1MEN1
SCHEMBL3378774 0.85 KIF11 (0.55) PTGS2KIF11HPGDGAAMAPK1
SCHEMBL3378764 0.85 PTGS2 (0.51) PTGS2KIF11HPGDGAAMAPK1
SCHEMBL3378931 0.85 KIF11 (0.67) PTGS2KIF11HPGDGAAMAPK1
SCHEMBL3377263 0.85 KIF11 (0.67) PTGS2KIF11DRD2HTR2AHTR2C
SCHEMBL3379785 0.84 GAA (0.49) KIF11HPGDGAAMAPK1CYP17A1
SCHEMBL3374111 0.82 GAA (0.50) KIF11HPGDGAAMAPK1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 PTGS2 439/4885KIF11 3561/4885FABP4 1067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.